August 26, 2021

Superfood Stock More than a Mushroom Company | Rritual Superfoods (RSF)

Midas Letter
Midas Letter
Superfood Stock More than a Mushroom Company | Rritual Superfoods (RSF)
/

Rritual Superfoods Inc (CNSX:RSF, OTCMKTS:RRSFF) is an award-winning brand focused on the emerging functional mushroom & adaptogenic superfood market.

With the superfood market projected to reach $275 billion by 2025, growing at 7.9% each year, Rritual aims to define the sector.

“Functional mushrooms have been around and used for relief, in inflation, in wellness for thousands of years. Its just, I really believe that we have come to the party. There really aren’t a lot of premium players we are. We have branded this well. We have come up with efficacious formula and really again its the right timing.” – Rritual Superfoods CEO David Kerbel

Rritual has a variety of plant-based elixirs for modern wellness currently on the market. In only its first year of sales in North America, the company has generated $8.4 million in sales. With its next tranche of products launching this year, such as its superfood latte powder mixes, the CEO is looking to double that number.

Currently, Rritual has 2,400 retail locations and over 10,000 points of distribution projected to grow to 6,000 stores and 20,000 points of distribution by the end of this year.

You may have seen Rritual’s products in the largest drugstore chain in the USA, CVS, or more recently as Amazon as the company has advanced its e-commerce capabilities.

Watch the full interview to learn about the functional & adaptogen mushroom market, superfoods mainstream adoption, and Rrituals scalability.

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.